ArticleInternational journal of cancer2021
Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients.
Open access · greenAbstract read
In one paragraph
Article in International journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications.Translational oncology · 2026Review
- Review
- Joint analysis of sQTL and Hi-C reveals spatial proximity between sQTLs and target genes in cancer tissues.Scientific reports · 2025Article
- Article
- Systematically identification of survival-associated eQTLs in a Japanese kidney cancer cohort.PLoS genetics · 2025Article
- Multiple myeloma.Nature reviews. Disease primers · 2024Review
- Utilizing 3D Models to Unravel the Dynamics of Myeloma Plasma Cells' Escape from the Bone Marrow Microenvironment.Cancers · 2024Review
- Personalized 3-Gene Panel for Prostate Cancer Target Therapy.Current issues in molecular biology · 2022Article
- FASTK family of genes linked to cancer.Bioinformation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
54 authors at 20 institutions in 12 countries.
Angelica MacaudaGenomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-9820-5079
Chiara PireddaDepartment of Biology, University of Pisa, Pisa, Italy.
Alyssa I Clay-GilmourDepartment of Epidemiology & Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.
Juan SainzGenomic Oncology Area, GENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada/Andalusian Regional Government, Granada, Spain.ORCID 0000-0002-9355-2423
Gabriele BudaClinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy.
Miroslaw MarkiewiczDepartment of Hematology and Bone Marrow Transplantation, SPSKM Hospital, Katowice, Poland.
Torben BaringtonDepartment of Clinical Immunology, Odense University Hospital, Odense, Denmark.
Elad ZivDepartment of Medicine, Division of General Internal Medicine, Institute for Human Genetics, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
Michelle A T HildebrandtDepartment of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-6769-6872
Alem A BelachewDepartment of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Judit VarkonyiThird Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
Witold PrejznerDepartment of Hematology and Transplantation, Medical University of Gdansk, Gdansk, Poland.
Agnieszka Druzd-SitekDepartment of Lymphoid Malignacies, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
John SpinelliCancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
Niels Frost AndersenDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Jonathan N HofmannDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Marek DudzińskiDepartment of Hematology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszow, Rzeszow, Poland.
Joaquin Martinez-LopezComplutense University, CNIO, CIBERONC, Hospital 12 de Octubre, Madrid, Spain.
Elzbieta Iskierka-JazdzewskaDepartment of Haematology, Copernicus Memorial Hospital, Lodz, Poland.
Roger L MilneCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
Grzegorz MazurDepartment of Internal and Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, Wroclaw, Poland.
Graham G GilesCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
Lene Hyldahl EbbesenDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Marcin RymkoDepartment of Hematology, N. Copernicus Town Hospital, Torun, Poland.
Krzysztof JamroziakDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Edyta SuboczDepartment of Haematology, Military Institute of Medicine, Warsaw, Poland.
Rui Manuel ReisLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
Ramon Garcia-SanzDepartment of Hematology, University Hospital of Salamanca, IBSAL, Salamanca, Spain.
Anna SuskaDepartment of Hematology, Jagiellonian University Medical College, Cracow, Poland.
Eva Kannik HaastrupDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Daria ZawirskaDepartment of Hematology, University Hospital of Cracow, Cracow, Poland.
Norbert GrzaskoDepartment of Experimental Hematooncolog, Medical University of Lublin, Lublin, Poland.
Annette Juul VangstedDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Charles DumontetCancer Research Center of Lyon/Hospices Civils de Lyon, Lyon, France.
Marcin KruszewskiDepartment of Hematology, University Hospital Bydgoszcz, Bydgoszcz, Poland.
Magdalena DutkaDepartment of Hematology and Transplantation, Medical University of Gdansk, Gdansk, Poland.
Nicola J CampUniversity of Utah, Salt Lake City, Utah, USA.
Rosalie G WallerUniversity of Utah, Salt Lake City, Utah, USA.
Waldemar TomczakMedical University of Lublin, Lublin, Poland.
Matteo PelosiniClinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy.
Małgorzata RaźnyDepartment of Hematology, Rydygier Specialistic Hospital, Cracow, Poland.
Herlander MarquesMolecular Oncology Research Center, Barretos, São Paulo, Brazil.
Niels AbildgaardDepartment of Hematology, Odense University Hospital, Odense, Denmark.
Marzena WątekHematology Clinic, Holycross Cancer Center, Kielce, Poland.
Artur JurczyszynDepartment of Hematology, Jagiellonian University Medical College, Cracow, Poland.
Elizabeth E BrownDepartment of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Sonja BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Aleksandra ButrymDepartment of Internal and Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, Wroclaw, Poland.
Celine M VachonGenetic Epidemiology and Risk Assessment Program, Mayo Clinic Comprehensive Cancer Center, and Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Aaron D NormanGenetic Epidemiology and Risk Assessment Program, Mayo Clinic Comprehensive Cancer Center, and Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Susan L SlagerGenetic Epidemiology and Risk Assessment Program, Mayo Clinic Comprehensive Cancer Center, and Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Federica GemignaniDepartment of Biology, University of Pisa, Pisa, Italy.
Federico CanzianGenomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-4261-4583
Daniele CampaDepartment of Biology, University of Pisa, Pisa, Italy.ORCID 0000-0003-3220-9944
University of Pisa · ITMayo Clinic in Arizona · USAarhus University Hospital · DKCopenhagen University Hospital · DKGdańsk Medical University · PLHospital de Câncer de Barretos · BRJagiellonian University · PLMedical University of Lublin · PLNational Cancer Institute · USOdense University Hospital · DKThe University of Melbourne · AUThe University of Texas MD Anderson Cancer Center · USUniversity of Utah · USWroclaw Medical University · PLBC Cancer Agency · CACopernicus Memorial Hospital · PLCracow University of Technology · PLGerman Cancer Research Center · DEGórnośląskie Centrum Medyczne · PLHoly Cross University · PL
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8MXRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9MUTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6MTRAINING AND CAREER DEVELOPMENTU54CA118948 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI UPENDER MANNE, Erica Michelle Stringer-Reasor · 2005 to 2026
$26.6MProject 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Yi Lin · 2015 to 2026
$25.5MCancer Prevention & Control Training ProgramR25CA047888 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DEMARK-WAHNEFRIED, WENDY, MENESES, KAREN M · 1988 to 2016
$11.2MMayo Cancer Genetic Epidemiology Training ProgramR25CA092049 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M., VACHON, CELINE M · 2001 to 2018
$5.3MPrevalence and Progression of Monoclonal GammopathiesR01CA107476 · NCI · MAYO CLINIC ROCHESTER · PI KUMAR, SHAJI KUNNATHU, RAJKUMAR, S VINCENT · 2004 to 2018
$4.6MGENETIC EPIDEMIOLOGY OF CHRONIC LYMPHOCYTIC LEUKEMIAR01CA134674 · NCI · UNIVERSITY OF UTAH · PI CAMP, NICOLA J. · 2010 to 2016
$3.8MOnset and biomarkers for progression of monoclonal gammopathiesR01CA168762 · NCI · MAYO CLINIC ROCHESTER · PI KUMAR, SHAJI KUNNATHU, RAJKUMAR, S VINCENT · 2012 to 2024
$3.2MIntegration of germline and tumor genomes in CLLR01CA235026 · NCI · MAYO CLINIC ROCHESTER · PI BRAGGIO, ESTEBAN, SLAGER, SUSAN L · 2019 to 2023
$3.2MMolecular characterization of myeloma and related asymptomatic precursor statesR01CA186646 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BROWN, ELIZABETH E, VACHON, CELINE M · 2014 to 2018
$3.0MNCI NIH HHS P30 CA013148NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA042014NCI NIH HHS P50 CA186781NCI NIH HHS R01 CA107476NCI NIH HHS R01 CA134674NCI NIH HHS R01 CA168762NCI NIH HHS R01 CA186646NCI NIH HHS R01 CA235026NCI NIH HHS R21 CA155951NCI NIH HHS R25 CA047888NCI NIH HHS R25 CA092049NCI NIH HHS U54 CA118948the National Institute of Health/National Cancer Institute P30 CA13148Wellcome Trust 209057
Abstract
Gene expression profiling can be used for predicting survival in multiple myeloma (MM) and identifying patients who will benefit from particular types of therapy. Some germline single nucleotide polymorphisms (SNPs) act as expression quantitative trait loci (eQTLs) showing strong associations with gene expression levels. We performed an association study to test whether eQTLs of genes reported to be associated with prognosis of MM patients are directly associated with measures of adverse outcome. Using the genotype-tissue expression portal, we identified a total of 16 candidate genes with at least one eQTL SNP associated with their expression with P < 10
Indexed as
Polymorphism, Single NucleotideQuantitative Trait LociAgedApyraseFemaleGene Expression ProfilingGenetic Association StudiesGerm-Line MutationHumansMaleMiddle AgedMitochondrial ProteinsMultiple MyelomaRNA-Binding ProteinsSurvival AnalysisApyraseENTPD1 protein, humanMitochondrial ProteinsRNA-Binding ProteinsTBRG4 protein, humaneQTLgenetic polymorphismsmultiple myelomaoverall survivalprogression-free survival
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.